On May 6, 2025, Wells Fargo analyst Stephen Baxter announced a modification in the price target for CVS Health (CVS, Financial), raising it from USD 76.00 to USD 84.00. This adjustment signifies a 10.53% increase over the previous target.
Despite this change in the price target, Wells Fargo maintains its "Overweight" rating for CVS Health (CVS, Financial), consistent with the prior assessment. The continued "Overweight" rating suggests that CVS Health is expected to outperform average market returns.
The adjustment in the price target reflects Wells Fargo's positive outlook on CVS Health's (CVS, Financial) future performance, aligning with the current market conditions and company strategies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CVS Health Corp (CVS, Financial) is $77.67 with a high estimate of $95.00 and a low estimate of $70.00. The average target implies an upside of 15.89% from the current price of $67.02. More detailed estimate data can be found on the CVS Health Corp (CVS) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CVS Health Corp's (CVS, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CVS Health Corp (CVS, Financial) in one year is $85.65, suggesting a upside of 27.79% from the current price of $67.023. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CVS Health Corp (CVS) Summary page.
